[1] Kaswala DH, Lai M, Afdhal NH. Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016. Dig Dis Sc, 2016, 61: 1356-1364. [2] Hashemi S, Alavian S, Gholamifesharaki M. Assessment of transient elastography (FibroScan) for diagnosis of fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Caspian J Intern Med, 2016, 7: 242-252. [3] Yao Y, Bao J, Lu Y, et al. Biomarkers of liver fibrosis detecting with electrochemical immunosensor on clinical serum. Sensor Actuat B-Chem, 2016, 222:127-132. [4] Henry B , Ziobro R , Becker K A , et al. Acid Sphingomyelinase.Handb Exp Pharmacol.2013,8:77-88. [5] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年1月修订). 中华内科杂志, 2010, 19:1-3. [6] Hubel E, Saroha A, Park WJ, et al. Sortilin deficiency reduces ductular reaction, hepatocyte apoptosis, and liver fibrosis in cholestatic-induced liver injury. Am J Pathol, 2016, 187:122-133. [7] Marí M, Morales A, Colell A, et al. Mitochondrial cholesterol accumulation in alcoholic liver disease: Role of ASMase and endoplasmic reticulum stress. Redox Biol, 2014, 3:100-108. [8] Moles A, Tarrats N, Morales A, et al. Acidic sphingomyelinase controls hepatic stellate cell activation and in vivo liver fibrogenesis.. Am J Pathol, 2010, 177: 1214-1224. [9] Haines D, Samuel GH,Cohen H,et al.Caveolin-1 is a negativeregulator of MMP-1 gene expressionin human dermal fibroblastsvia in hibition of Erk1/2/Ets 1signaling pathway.Dermatol Sci.2011,8:210-216. |